Edgestream Partners L.P. bought a new position in shares of Globus Medical, Inc. (NYSE:GMED – Free Report) during the third quarter, HoldingsChannel reports. The fund bought 91,681 shares of the medical device company’s stock, valued at approximately $6,867,000.
Other institutional investors also recently modified their holdings of the company. Sanctuary Advisors LLC lifted its stake in shares of Globus Medical by 2.3% in the 1st quarter. Sanctuary Advisors LLC now owns 6,611 shares of the medical device company’s stock valued at $570,000 after acquiring an additional 151 shares during the last quarter. Summitry LLC grew its position in Globus Medical by 2.6% during the 1st quarter. Summitry LLC now owns 8,205 shares of the medical device company’s stock worth $707,000 after acquiring an additional 211 shares during the last quarter. Central Pacific Bank Trust Division grew its position in Globus Medical by 7.8% during the 3rd quarter. Central Pacific Bank Trust Division now owns 3,057 shares of the medical device company’s stock worth $229,000 after acquiring an additional 220 shares during the last quarter. Arizona State Retirement System grew its position in Globus Medical by 0.8% during the 2nd quarter. Arizona State Retirement System now owns 31,077 shares of the medical device company’s stock worth $2,455,000 after acquiring an additional 252 shares during the last quarter. Finally, Angeles Wealth Management LLC increased its holdings in Globus Medical by 5.0% in the 2nd quarter. Angeles Wealth Management LLC now owns 5,894 shares of the medical device company’s stock worth $466,000 after purchasing an additional 280 shares in the last quarter. 95.16% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
Several equities analysts have commented on GMED shares. Needham & Company LLC dropped their target price on Globus Medical from $117.00 to $100.00 and set a “buy” rating for the company in a research report on Friday, November 6th. BTIG Research restated a “neutral” rating on shares of Globus Medical in a report on Friday, November 6th. Truist Financial lowered their target price on Globus Medical from $100.00 to $90.00 and set a “buy” rating for the company in a research report on Monday, November 9th. Royal Bank Of Canada reduced their price target on Globus Medical from $115.00 to $85.00 and set an “outperform” rating on the stock in a research report on Thursday, October 1st. Finally, UBS Group assumed coverage on Globus Medical in a research report on Tuesday, July 28th. They set a “neutral” rating and a $82.00 price objective for the company. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and seven have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $96.08.
Check Out Our Latest Stock Analysis on Globus Medical
Globus Medical Stock Down 0.5%
Shares of NYSE GMED opened at $70.14 on Wednesday. The company has a market capitalization of $9.29 billion, a PE ratio of 17.23, a P/E/G ratio of 1.09 and a beta of 0.98. Globus Medical, Inc. has a twelve month low of $69.49 and a twelve month high of $101.40. The firm has a fifty day simple moving average of $76.31 and a 200 day simple moving average of $82.50.
Globus Medical (NYSE:GMED – Get Free Report) last issued its quarterly earnings results on Thursday, November 5th. The medical device company reported $1.23 EPS for the quarter, beating analysts’ consensus estimates of $1.20 by $0.03. The business had revenue of $763.72 million for the quarter, compared to analysts’ expectations of $792.39 million. Globus Medical had a net margin of 17.76% and a return on equity of 14.43%. The business’s quarterly revenue was down .7% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.18 earnings per share. Globus Medical has set its FY 2026 guidance at 4.950-5.050 EPS. As a group, equities analysts expect that Globus Medical, Inc. will post 4.98 earnings per share for the current fiscal year.
Insider Activity
In related news, Director Ann D. Rhoads sold 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 4th. The stock was sold at an average price of $85.00, for a total transaction of $425,000.00. Following the completion of the sale, the director owned 35,384 shares of the company’s stock, valued at $3,007,640. This trade represents a 12.38% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director James Tobin sold 41,666 shares of Globus Medical stock in a transaction that occurred on Tuesday, November 10th. The stock was sold at an average price of $75.16, for a total value of $3,131,616.56. Following the completion of the sale, the director owned 15,000 shares of the company’s stock, valued at approximately $1,127,400. The trade was a 73.53% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 76,666 shares of company stock valued at $5,794,017. Corporate insiders own 18.38% of the company’s stock.
About Globus Medical
Globus Medical is a medical device company focused on musculoskeletal care. Its products include implants and instruments used in spine surgery, as well as solutions for orthopedic trauma and other orthopedic procedures. The company also develops surgical technologies, including robotic navigation and imaging systems designed to support planning and guidance during procedures. Its portfolio expanded significantly in 2023 when Globus Medical completed its combination with NuVasive, a provider of spine care products and technologies.
See Also
- Five stocks we like better than Globus Medical
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Want to see what other hedge funds are holding GMED? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Globus Medical, Inc. (NYSE:GMED – Free Report).
Receive News & Ratings for Globus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Globus Medical and related companies with MarketBeat.com's FREE daily email newsletter.
